Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Squamous Intraepithelial Lesions 1Prolactinoma 1Precancerous Conditions 1Pituitary Neoplasms 1Growth Hormone-Secreting Pituitary Adenoma 1Gliosarcoma 1Glioblastoma 1Central Nervous System Neoplasms 1Anus Neoplasms 1Adenoma, Chromophobe 1Adenoma, Basophil 1Adenoma, Acidophil 1

Interventions

Temozolomide 46Radiotherapy 36Bevacizumab 34Carmustine 13Erlotinib Hydrochloride 11Irinotecan 10sargramostim 7Thalidomide 7Chemotherapy, Adjuvant 7Carboplatin 7Radiation 6pembrolizumab 5Topotecan 5Magnetic Resonance Spectroscopy 5Filgrastim 5Drug Therapy 5Cyclophosphamide 5aldesleukin 4Tamoxifen 4Surgical Procedures, Operative 4Sorafenib 4O(6)-benzylguanine 4Gefitinib 4Etoposide 4Celecoxib 4cediranib 3Radiotherapy, Intensity-Modulated 3Radiotherapy, Conformal 3Peripheral Blood Stem Cell Transplantation 3Imatinib Mesylate 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gliosarcoma × DNA Methylation × Clear all
NCT01149850 2024-09-19

Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

Jonsson Comprehensive Cancer Center

Phase 2 Completed
50 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡